HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinicalstage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib minor resection study of HRX-215. Five patients in the clinical trial were treated with HRX-215 for a period of 28 days after a minor liver resection […]
ENYO Pharma Announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect Company […]
Nutrium Raises $12 million in Series A Funding Round Led by Vesalius Biocapital
And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient Investment seen as further validation of the corporate nutrition benefit market and its ability to manage workforce health and costs. LISBON, Portugal, Sept. 16, 2025 /PRNewswire/ – Nutrium, an all-in-one corporate nutrition solution that helps millions of patients worldwide create personalized meal plans, […]
ENYO PHARMA announces completion of series C financing with VESALIUS BIOCAPITAL
And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient ENYO completes €32 million Series C with new €6 million investment from Vesalius Biocapital IV New funds will support two additional clinical studies and expand preclinical research, including in ADPKD Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in […]
HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration
Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available […]
Inflammatix Raises $57M in Series E Financing
Inflammatix Raises $57M in Series E Financing NEW YORK, Sep 12, 2024 — Molecular diagnostics firm Inflammatix said Thursday that it has raised $57 million in a Series E funding round. The round was led by Khosla Ventures and Think.Health with participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, and […]
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver Regeneration
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver Regeneration Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins […]
Inheart raises $11M to accelerate development & deployment of novel therapeuthic, predictive, and screening cardiac solutions
Inheart raises $11M to accelerate development & deployment of novel therapeuthic, predictive, and screening cardiac solutions Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum May 6, 2024 — […]
Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions
Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 – Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius […]
Vesalius Biocapital: First Close
Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million Significant support from investors including the European Investment Fund Fund to invest in first and best-in-class European life science companies in drug development and digital health Luxembourg-Strassen, 29 June 2023 – Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first […]